boceprevir (victrelis) Report issue

Small molecule Approved FDA First in Class Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Boceprevir (trade name Victrelis) is first-generation, selective, small molecule inhibitor of the non-structural serine protease (NS3) and NS4A polypeptide complex (NS3/NS4A) and is a direct acting antiviral drug against the hepatitis C virus. It is indicated the treatment of chronic hepatitis C (CHC) genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients (18 years of age and older) with compensated liver disease, including cirrhosis, who are previously untreated or who have failed previous interferon and ribavirin therapy. Boceprevir is not approved as a monotherapy. Upon administration, boceprevir reversibly binds to the active center of the HCV NS3/NS4A and prevents NS3/NS4A protease-mediated polyprotein maturation. This disrupts the processing of viral proteins and the formation of a viral replication complex, which inhibits viral replication in HCV genotrype 1-infected host cells. NS3, a serine protease, is essential for the proteolytic cleavages within the HCV polyprotein and plays a key role during HCV viral RNA replication. NS4A is an activating factor for NS3.   NCATS

Chemistry

  • SMILES: CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC3CCC3)C(=O)C(N)=O)C2(C)C)C(C)(C)C
  • InChIKey: LHHCSNFAOIFYRV-DOVBMPENSA-N
  • Mol. Mass: 519.6767
  • ALogP: 1.71
  • ChEMBL Molecule:
    boceprevir  
More Chemistry

Pharmacology

Alternative names

beceprevir | boceprevir | n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide | sch503034 | sch 503034 | sch-503034 | victrelis | victrellis

Organizations (48)

Research & Development (48)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (14)

Approved Indications (1)


 

Hepatitis C, Chronic

Experimental Indications - Clinical Trial Phases 1-4 (14)


 

Coinfection (Phase 3)

Healthy Volunteers (Phase 1/Phase 2)

Hepacivirus (Phase 2/Phase 3)

Hepatitis (Phase 4)

Hepatitis C (Phase 4)

Hepatitis C, Chronic ()

HIV (Phase 4)

HIV Infections (Phase 4)

Kidney Failure, Chronic (Phase 4)

Liver Cirrhosis, Experimental (Phase 2)

Liver Transplantation (Phase 3)

Menopause (Phase 3)

Stomach Diseases (Phase 1)

Thrombocytopenia (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 52
  • # of Trial Organizations: 48

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue